Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
UTHR 
United Therapeutics Corporation (UTHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: UTHR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $513
1 Year Target Price $513
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 58.3% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.33B USD | Price to earnings Ratio 17.02 | 1Y Target Price 513 |
Price to earnings Ratio 17.02 | 1Y Target Price 513 | ||
Volume (30-day avg) 14 | Beta 0.87 | 52 Weeks Range 266.98 - 479.50 | Updated Date 11/7/2025 |
52 Weeks Range 266.98 - 479.50 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 26.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When - | Estimate 7.31 | Actual 7.16 |
Profitability
Profit Margin 40.65% | Operating Margin (TTM) 48.69% |
Management Effectiveness
Return on Assets (TTM) 13.14% | Return on Equity (TTM) 20.04% |
Valuation
Trailing PE 17.02 | Forward PE 15.29 | Enterprise Value 16933833621 | Price to Sales(TTM) 6.18 |
Enterprise Value 16933833621 | Price to Sales(TTM) 6.18 | ||
Enterprise Value to Revenue 5.5 | Enterprise Value to EBITDA 9.8 | Shares Outstanding 43056599 | Shares Floating 39829937 |
Shares Outstanding 43056599 | Shares Floating 39829937 | ||
Percent Insiders 1.85 | Percent Institutions 101.84 |
Upturn AI SWOT
United Therapeutics Corporation
Company Overview
History and Background
United Therapeutics Corporation was founded in 1996 by Martine Rothblatt. It focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases.
Core Business Areas
- Pulmonary Hypertension (PH): Develops and commercializes therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Organ Transplantation: Focuses on developing technologies for manufactured organs to solve the shortage of transplantable organs.
Leadership and Structure
Martine Rothblatt is the Chairperson and CEO. The company has a structured organizational hierarchy with functional departments and a board of directors.
Top Products and Market Share
Key Offerings
- Remodulin (treprostinil) Injection: A prostacyclin analogue for PAH. Competitors include generics of treprostinil, and other PAH therapies. Revenue from Remodulin was significant portion of total revenue. Estimated market share of treprostinil products vary depending on the formulation.
- Tyvaso (treprostinil) Inhalation Solution and DPI: An inhaled prostacyclin analogue for PAH and PH-ILD. Competitors include inhaled iloprost and other PAH therapies. Tyvaso DPI expanding the inhalable market. Sales growth has been strong.
- Orenitram (treprostinil) Extended-Release Tablets: An oral prostacyclin analogue for PAH. Competitors include other oral PAH therapies. Oral delivery improves convenience for patients. Has struggled against generics and other oral options.
- Adcirca (tadalafil): A PDE5 inhibitor for PAH. Competitors include sildenafil and other PDE5 inhibitors. Adcirca is now sold as an authorized generic. Declining sales due to generic entry.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the segment for rare diseases like pulmonary hypertension, is characterized by high R&D costs, regulatory hurdles, and patent protection. Organ transplantation field is emerging and very competitive.
Positioning
United Therapeutics is a leader in PAH therapies with a strong focus on innovation and addressing unmet needs. The company is pioneering organ manufacturing.
Total Addressable Market (TAM)
The global PAH market is estimated to be in the billions of dollars, and the organ transplantation market is projected to reach tens of billions. United Therapeutics is striving to capture a significant share of both markets. The organ manufacturing is still emerging but has significant future potential
Upturn SWOT Analysis
Strengths
- Strong product portfolio in PAH
- Innovative research and development
- Leadership in organ manufacturing
- Experienced management team
- Strong balance sheet
Weaknesses
- Reliance on treprostinil-based products
- Competition from generics
- Regulatory risks associated with new drug approvals
- High R&D expenses
Opportunities
- Expansion into new markets
- Development of new therapies for PAH and other diseases
- Advancements in organ manufacturing
- Potential acquisitions
- Partnerships and collaborations
Threats
- Increasing competition
- Patent expirations
- Changes in healthcare regulations
- Economic downturn
- Clinical trial failures
Competitors and Market Share
Key Competitors
- VTRS
- JAZZ
- LLY
Competitive Landscape
United Therapeutics has an edge in certain PAH therapies and the nascent organ manufacturing space. Generic competition is a major threat. Other competitors have a more diverse portfolios.
Major Acquisitions
Unither Bioelectronics
- Year: 2021
- Acquisition Price (USD millions): 200
- Strategic Rationale: To expand the capabilities for drug delivery using innovative electronic devices
Growth Trajectory and Initiatives
Historical Growth: United Therapeutics has experienced revenue growth driven by its PAH therapies, although growth has been impacted by generic competition. Profitability has fluctuated due to R&D expenses and competition.
Future Projections: Analysts project continued growth driven by Tyvaso DPI and the organ manufacturing segment. Projections also depend on successful clinical trials.
Recent Initiatives: Recent initiatives include the launch of Tyvaso DPI and continued investments in organ manufacturing.
Summary
United Therapeutics is a unique biopharmaceutical company specializing in PAH and pioneering organ manufacturing. Their success is driven by PAH therapies like Tyvaso, but faces generic competition. The company has potential in organ manufacturing but high R&D investments remain a risk. The company's future prospects depend on its pipeline and expansion of new therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About United Therapeutics Corporation
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 1999-06-17 | Founder, Chairman & CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1305 | Website https://www.unither.com |
Full time employees 1305 | Website https://www.unither.com | ||
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.